Published in Lab Business Week, December 31st, 2006
Under the agreement, Bacterin receives rights to Osteotech patents relating to flowable demineralized bone powder compositions.
The intellectual property made available through the licensure is complementary and synergistic with Bacterin's current osteobiologic product portfolio. This relationship will assist Bacterin in developing new options for transplant recipients, ultimately improving their quality of life.
"This is another significant milestone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.